Detalhe da pesquisa
1.
Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library.
ACS Med Chem Lett
; 11(6): 1175-1184, 2020 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32550998
2.
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497).
J Med Chem
; 61(3): 650-665, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29211475
3.
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.
J Med Chem
; 60(23): 9617-9629, 2017 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29111717
4.
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
J Med Chem
; 57(11): 4720-44, 2014 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24819116
5.
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
J Med Chem
; 57(4): 1170-87, 2014 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24432909
6.
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
Cancer Res
; 70(24): 10090-100, 2010 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20952508